SciBase's Capital Raising Initiatives Explained
SciBase Holding AB (NASDAQ: SCIB) recently shared the preliminary results of its capital raising efforts, which includes a significant rights issue and a directed issue. This capital raise aims to bolster the company's finances and facilitate future growth, reflecting SciBase's robust approach to developing advanced technologies in dermatology.
Understanding the Directed Issue
The directed issue was a strategic move, which bypassed existing shareholders' preferential rights, raising approximately SEK 22.5 million. All 16,669,624 units from this issue have been fully subscribed and paid for, demonstrating strong investor interest. The Board plans to allocate these units, with resolutions expected to follow soon.
Details of the Rights Issue
The rights issue contributed around SEK 59.3 million to the company. Preliminary outcomes indicated that 22,916,119 units, or roughly 52.2 percent, were successfully subscribed, contributing to a healthy amount of initial funding. This success was buoyed by subscriber commitments and intentions to back the offering, which ensured that owned commitments would remain unused.
Company's Increased Share Capital
As a direct outcome of the rights issue, the share capital of SciBase increased by SEK 3,437,417.85, bringing its new total to SEK 14,414,338.05. The overall share count expanded from 219,538,404 to 288,286,761 shares, resulting in a 23.8 percent dilution effect. Similarly, additional shares from the directed issue further boosted the company's total shares to 338,295,633, increasing capital by another SEK 2,500,443.60.
Growth Opportunities Through Warrants
Another key element of the capital raise includes attached warrants, which can allow for additional funding if they are exercised. If all warrants from the recent capital initiatives were to be utilized, SciBase could receive an added SEK 53.4 million to SEK 89.1 million. This shows the proactive planning by SciBase's management to ensure sustainable growth and enhanced financial health.
The Essence of Trading in BTU
Investors can continue trading the paid subscribed units on Nasdaq First North Growth Market until the designated period ends. The ability to actively trade these units gives investors flexibility while the company works on leveraging these funds.
Strategic Advisory Support
SciBase has collaborated with leading advisors such as Penser by Carnegie, who provided crucial financial advice, and Advokatfirman Schjødt, serving as the legal advisor. Their expertise is instrumental in navigating the complexities associated with such capital raises, ensuring that all regulatory requirements are met effectively.
About SciBase's Technological Advancements
At its core, SciBase is committed to revolutionizing dermatology with its unique point-of-care platform, Nevisense. This technology integrates artificial intelligence (AI) with advanced electrical impedance spectroscopy (EIS) to enhance diagnostic accuracy. By focusing on early detection and prevention, SciBase aims to significantly improve patient outcomes while simultaneously reducing healthcare costs.
With over two decades of dedicated research conducted at the prestigious Karolinska Institute in Stockholm, SciBase has positioned itself as a leader in medical technology. The company is dedicated to minimizing patient suffering and empowering clinicians to improve lives with timely interventions.
Frequently Asked Questions
What is the capital raise amount for SciBase?
SciBase's capital raising initiatives include a rights issue of approximately SEK 59.3 million and a directed issue of around SEK 22.5 million.
How many shares will SciBase have after the capital raise?
Post-capital raise, SciBase will have a total of 338,295,633 shares.
What is the function of the warrants issued?
The warrants allow investors to potentially subscribe for new shares, which could bring in an additional SEK 53.4 million to SEK 89.1 million.
When will trading in the paid subscribed units end?
Trading for the paid subscribed units will continue until January 17, 2025.
Who are the advisors involved in this capital raising?
SciBase engaged Penser by Carnegie as the financial advisor and Advokatfirman Schjødt as the legal advisor for this initiative.
